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Abstract
Background: Protein tyrosine phosphatase receptor gamma (PTPRG) is a ubiquitously expressed member of the
protein tyrosine phosphatase family known to act as a tumor suppressor gene in many different neoplasms with
mechanisms of inactivation including mutations and methylation of CpG islands in the promoter region. Although
a critical role in human hematopoiesis and an oncosuppressor role in chronic myeloid leukemia (CML) have been
reported, only one polyclonal antibody (named chPTPRG) has been described as capable of recognizing the native
antigen of this phosphatase by flow cytometry. Protein biomarkers of CML have not yet found applications in the
clinic, and in this study, we have analyzed a group of newly diagnosed CML patients before and after treatment.
The aim of this work was to characterize and exploit a newly developed murine monoclonal antibody specific for
the PTPRG extracellular domain (named TPγ B9-2) to better define PTPRG protein downregulation in CML patients.
Methods: TPγ B9-2 specifically recognizes PTPRG (both human and murine) by flow cytometry, western blotting,
immunoprecipitation, and immunohistochemistry.
Results: Co-localization experiments performed with both anti-PTPRG antibodies identified the presence of isoforms
and confirmed protein downregulation at diagnosis in the Philadelphia-positive myeloid lineage (including
CD34+/CD38bright/dim cells). After effective tyrosine kinase inhibitor (TKI) treatment, its expression recovered in
tandem with the return of Philadelphia-negative hematopoiesis. Of note, PTPRG mRNA levels remain unchanged in tyrosine
kinase inhibitors (TKI) non-responder patients, confirming that downregulation selectively occurs in primary CML cells.
Conclusions: The availability of this unique antibody permits its evaluation for clinical application including the
support for diagnosis and follow-up of these disorders. Evaluation of PTPRG as a potential therapeutic target
is also facilitated by the availability of a specific reagent capable to specifically detect its target in various
experimental conditions.
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Background
Protein kinases and phosphatases act in a coordinated man-
ner enabling precise regulation of signaling responses [1].
Protein tyrosine phosphatase receptor gamma (PTPRG) be-
longs to subtype V of the receptor-type protein tyrosine
phosphatases (PTPs) and possesses an extracellular region,
a single transmembrane region, and two tandem intracyto-
plasmic catalytic domains. Membranous and/or cytoplas-
mic PTPRG expression has been detected in leukocytes,
including hematopoietic precursors, the vast majority of
epithelial and endocrine cells of various organs [2–4].
PTPRG is a candidate tumor suppressor gene, and loss of
function by mutation, deletion, or loss of heterozygosity
have been associated with different types of tumors [5–7].
We have previously demonstrated that methylation-
driven downregulation of PTPRG expression occurs in
chronic myeloid leukemia (CML). Forced overexpression
of PTPRG led to reduced tyrosine phosphorylation, de-
creased clonogenic capability, and induction of apoptosis
in CML cells. In the same study, we have shown that
BCR-ABL1, the key deregulated kinase in CML, is a bio-
chemical substrate for PTPRG [8]. Two epitope-specific
antisera against the extracellular domain (ECD) of
PTPRG have previously been developed from rabbit [9]
and chicken [10]. However, polyclonal antibodies do not
represent an unlimited source of antibody, and variabil-
ity in the preparation and batch might affect specificity,
affinity, and avidity toward the antigen. Conversely,
monoclonal antibodies represent virtually unlimited and
homogeneous sources of reagents, as they are derived
from immortalized cells (hybridomas) and have applica-
tions in virtually all areas of biology and medicine. Early
diagnosis and cure for patients with CML represent
significant clinical challenges because of disease progres-
sion from chronic phase (CP) into a rapidly fatal blast
crisis (BC). Few protein biomarkers have been described
and implemented for CML diagnosis or management,
most are overexpressed, often not CML specific and,
overall, need to be better characterized and validated in
the clinic [11–14]. An exception to this general picture
might be CD26 and IL1RAP that were very recently de-
scribed as a CD34+/CD38− CML leukemia stem cell
(LSC)-associated biomarker [15–17]. Overall cell surface
antigens deserve more in-depth characterization as they
have the potential to represent a complementary, robust,
and straightforward method for monitoring the disease
and may represent potential therapeutic targets [11–13].
In the present study, we describe a new monoclonal
antibody developed against the ECD of human PTPRG.
The antibody, named TPγ B9-2, was found to react
against both human and murine PTPRG and was tested
for immunoblotting, immunoprecipitation, immunohis-
tochemistry, and flow cytometry applications. Its versa-
tility across a wide range of applications validates this
new antibody as a critical advance and a powerful tool
to provide a more detailed characterization of the tumor
suppressor gene PTPRG in the context of human and
murine cells and tissues, including evaluation of clinical
samples.
Methods
Additional procedures are described in detail in the
Additional file 1.
Production of anti-PTPRG monoclonal antibody
Mouse hybridoma cell lines were produced by ARETA
International srl (Gerenzano VA, Italy) from BALB-C
mice that were challenged with the purified ECD of
human PTPRG (ENST00000295874, NM_002841.3).
The ECD complementary DNA (cDNA) was cloned in a
pCEP4 vector containing an in-frame, carboxy-terminal
murine IgG3-Fc portion used as a tag for purification
purposes. The vector was kindly provided by Dr. Maria
Laura Belladonna, University of Perugia, Italy. The construct
obtained, named pCEP4-Fc-ECD, was transduced into the
HEK293F human embryonic kidney cell line. The cells were
cultured in protein-free medium CD293® (Thermo Fisher,
Milan, Italy) with 50 μM β-mercaptoethanol and 0.5 mg/mL
of hygromycin (Thermo Fisher, Milan, Italy). Conditioned
medium was collected, and fusion protein was purified
(>95%) by protein-G affinity chromatography. Individual hy-
bridoma clones were first evaluated by direct ELISA assay
using the purified ECD, the Fc portion of which was cleaved
off to identify and remove all the clones recognizing the tag.
Supernatants from individual subclones were screened
on the basis of capability to recognize the native antigen
expressed on the surface of peripheral blood monocytes
by flow cytometry. After a further round of subcloning
from a positive candidate, the TPγ B9-2 clone (IgG1)
was selected.
Primary cell samples
Fresh leukapheresis or peripheral blood samples were
obtained with written informed consent from patients
with CP CML at diagnosis prior to treatment or non-
CML donors. We have determined the expression levels
of PTPRG by real-time quantitative polymerase chain re-
action (RQ-PCR) in peripheral blood in 39 CML patients
at presentation and after treatment with tyrosine kinase
inhibitors (TKIs) (Additional file 1: Table S2). CML pa-
tients included in this study were diagnosed in CP at the
San Francesco Hospital, Nuoro, and at the National
Center for Cancer Care and Research (NCCCR), Hamad
Medical Corporation (HMC), Doha-Qatar. The study
was approved by the Local Ethics Committee, ASL
Nuoro (Permit Number: 1276), AOUI Verona (Permit
Number: 25066), and Hamad Medical Center, Doha,
Qatar (HMC Permit Number: 2011/1118). Informed
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consent in accordance with the declaration of Helsinki
was obtained from each patient. Fresh samples used for
flow cytometry (24 CML and 13 G-CSF mobilized
individuals, mean age 30, range 11–53, eight males, five
females) were used as whole blood or, in selected cases,
were enriched for CD34+ cells using CliniMACS (Miltenyi
Biotec Inc., Auburn, CA, USA) according to the manufac-
turer’s instructions or as previously reported [18].
Results
Immunoprecipitation and western blotting analysis
We have developed a monoclonal antibody using as anti-
gen the whole ECD of PTPRG purified from cDNA-
transfected HEK293F cells. The antigen is a glycoprotein,
the epitopes of which can greatly influence the capability
of the resulting antibodies to recognize the native antigen.
We previously evaluated the capability of affinity-purified
TPγ B9-2 to recognize the full-length protein by immuno-
precipitation in the K562 cell line transfected with PTPRG
cDNA [8]. Glioblastoma expresses one of the highest
levels of PTPRG [19]. Here, by western blotting, we con-
firmed specificity of TPγ B9-2 in a glioblastoma cell line
DBTRG overexpressing endogenous PTPRG (Fig. 1a).
We next specifically downregulated PTPRG using
siRNA in K562 expressing PTPRG cDNA under the
control of the CMV promoter [8] (Fig. 1b) and in
DBTRG (Fig. 1 c–d) PTPRG expressing cells.
Of note in DBTRG cells, where PTPRG is endogenously
expressed, both monoclonal TPγ B9-2 and chPTPRG rec-
ognized two isoforms of PTPRG (Fig. 1a), the putative
full-length protein of approximately ≈180 kDa and minor
≈150 and ≈100 kDa putative processing products that
were reported to come up when the protein is overex-
pressed [9].
Fig. 1 TPγ B9-2 specifically recognizes PTPRG. Downregulation of PTPRG by siRNA demonstrates the specificity of TPγ B9-2 monoclonal antibody
for the antigen. Immunoblotting was performed with the indicated antibodies after transfection with a specific PTPRG siRNA (siRNA) and with a
negative control siRNA (scrambled: SCR). Cell lines were DBTRG and K562, and antibodies were Mab TPγ B9-2 or the reference rabbit polyclonal
antibody RbtP4 and chicken (ch) anti PTPRG [9, 10]. a Immunoprecipitation of PTPRG by TPγ B9-2 monoclonal antibody. K562 and DBTRG cell
lines, respectively negative and positive for PTPRG mRNA expression, were subjected to immunoblotting analysis with chPTPRG antibody after
immunoprecipitation with TPγ B9-2 antibody. Left side: Black arrow, full-length PTPRG; gray arrows indicate putative processed forms. No signal
was detectable using an irrelevant antibody for IP (data not shown). b Western blotting with mab TPγ B9-2 or the reference rabbit polyclonal antibody
RbtP4 in PTPRG expressing DBTRG cell line treated with scrambled (SCR) or PTPRG-specific siRNA. Both antibodies detect the downregulation of PTPRG.
Anti-β-actin was used as a loading control. c Western blotting with mab TPγ B9-2 or the reference rabbit polyclonal antibody RbtP4 in PTPRG silenced
K562 cell lines overexpressing PTPRG (K562 PTPRG+). Downregulation of the 180 kDa band is apparent in silenced cells using both antibodies.
Differences in signal intensities are due to the combined effect of individual affinities of primary antibodies toward the native or cDNA-
transfected antigens and secondary antibodies toward the murine or rabbit Igs
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Immunohistochemistry analysis
Human and murine ECDs of PTPRG (accession num-
bers AAA60224.1 and Q05909, respectively) share 91.2%
identity and 95.0% similarity at the amino acid level as
calculated using the Needleman-Wunsch global align-
ment algorithm. Therefore, cross-reactivity of the anti-
body between these species was predictable. To evaluate
this possibility and unequivocally establish the capability
of the antibody to specifically recognize the antigen, we
tested a tissue sample of Ptprg-null (KO) and matched
heterozygous mice [20] as negative and positive controls,
respectively. TPγ B9-2 recognized PTPRG only in sam-
ples obtained from the testis of control heterozygous
mice (Fig. 2a, left). The specificity of the signal was
further confirmed by the positive staining obtained with
a previously validated antibody developed in chicken
(named chPTPRG) against the 20 amino acid peptide
CZNEDEKEKTFTKDSDKDLK, a highly conserved se-
quence among vertebrates with a 100% homology among
human, mouse, and rat (Fig. 2a, right) [19]. The TPγ B9-
2 antibody also recognized human formalin-fixed,
paraffin-embedded tissues, as shown in Fig. 2b (a, d).
This experiment further demonstrated the specificity of
the staining as well as the identity of the histological
structures highlighted by the monoclonal antibody as we
reacted samples from the normal lung and pancreas with
two additional polyclonal antibodies we previously devel-
oped in chicken and rabbit against extracellular epitopes
of the antigen (named chPTPRG and RbtP4), respect-
ively (Fig. 2b (b, e and c, f )) [19, 21]. All the antibodies
showed an overlapping pattern of staining, with no de-
tectable signal when matched with irrelevant controls
used in consecutive sections (insets). All the antibodies
recognized lung macrophages (black arrows; Fig. 2b
(a–c)) and endocrine cells within the pancreas (Islets
of Langerhans, white arrows), along with centroacinar
cells (black arrow; Fig. 2b (d–f )), as previously described
[21]. The chPTPRG stained exocrine cells more diffusely
[19, 22]. As PTPRG is known to be expressed in various
isoforms, this result might be explained by the presence of
a differentially spliced/processed form of the phosphatase
within pancreatic tissue.
Once we demonstrated the specificity of the reagents
employed, we then assessed whether the monoclonal
and chicken antibodies shared the same epitope by treat-
ing the same murine brain section with both antibodies.
One was directly labeled with Alexa fluor 488 (TPγ B9-
2), while the second (chPTPRG) was visualized using a
NorthernLights 637 Fluorochrome-labeled secondary
antibody. The results suggested that the epitopes
Fig. 2 In situ analysis of PTPRG expression. a Immunohistochemistry using monoclonal TPγ B9-2 and chPTPRG antibodies on cryostatic sections
of mouse testis. In the heterozygous PTPRG (+/−) mice, shown in the insets, the two antibodies recognize the same structures while in Ptprg-null
(KO) (−/−) mice, shown as the main figure, no staining was detectable. b Comparison between TPγ B9-2, chPTPRG, and RbtP4 in normal human
lung (a–c) and pancreas (d–f). Formalin-fixed, paraffin-embedded sections were stained with anti-PTPRG antibodies indicated. All the antibodies
recognize lung alveolar macrophages (a–c, arrows). In pancreas (d–f) TPγ B9-2 preferentially stains Islets of Langerhans (white arrows) and centroacinar
regions (black arrows), while chPTPRG stains the tissue more diffusely, including the exocrine glands. Matched irrelevant antibodies controls (murine
IgG1, IgY, and rabbit IgG) are shown in the insets
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recognized are different as minor differences among
subcellular structures were observed, despite an almost
complete overlapping of the histo-cytologic details rec-
ognized by both antibodies as shown by Fig. 3c, g (co-
localization of both antibodies) and Fig. 3d, h (merging
of both antibodies). Indeed, while both TPγ B9-2 (Fig. 3a)
and chPTPRG (Fig. 3b) antibodies correctly recognized
the neuronal soma in murine brain, only the latter rec-
ognized the dendrites (white arrow), again suggesting
that the antibodies can recognize different isoforms of
the phosphatase.
Flow cytometry analysis
The TPγ B9-2 antibody was originally selected for its
capability to specifically recognize the antigen by flow
cytometry, as no commercial antibody had been re-
ported for this important application. We evaluated TPγ
B9-2 capability to detect the native form of PTPRG by
performing a side-by-side comparison of the capability
of chPTPRG and TPγ B9-2 antibodies to recognize the
same major leukocyte subpopulations (gating strategy
displayed in upper Fig. 4) in peripheral blood of normal
donors (lower Fig. 4). In a population of CD45+ cells, we
observed that both antibodies readily recognized CD14+
monocytes, CD16+ neutrophils, CD19+ B cells, CD16−
eosinophils, and CD34+ progenitor cells. We observed
lower/undetectable levels of PTPRG expression in CD3+
T cells (Fig. 4). These results are in line with those previ-
ously obtained using the chicken antibody [10]. In
Fig. 5a–c, we have compared side-by-side the mean
fluorescence intensity (MFI) measured in the same cell
populations of a series of normal individuals and CML
patients (see Additional file 1: Table S1 for details) using
TPγ B9-2 and chPTPRG antibodies and confirmed
PTPRG downregulation in monocytes (p = 0.0017) and
PMN (p < 0.0001) in CML patients in comparison with
healthy controls (Fig. 5a–c). The downregulation of
PTPRG was shown across both mature and primitive
CD34 subsets (p = 0.0068; CD34+CD38bright and p =
0.0002; CD38dim cells (Fig. 5d)). We then built a receiver
operating characteristic curve (ROC curve) for normal
individuals and CML patients. A statistically significant
capability to discriminate between CML and healthy
subject is achieved when monocytes and PMN are evalu-
ated. No/negligible expression of PTPRG in lymphocytes
renders these cells unsuitable for the purpose (Fig. 6).
Downregulation of PTPRG in CML and recovery of normal
PTPRG+ cells during the remission phase of the disease
Finally, we asked whether we could confirm and ex-
tend our previous observation regarding the loss of
PTPRG in CML [8]. We performed a retrospective
analysis of a group of 39 CML patients (described in
Additional file 1: Table S2) evaluated at diagnosis and
after the indicated treatment by measuring PTPRG
messenger RNA (mRNA) levels by RQ-PCR. Among
these, we could perform analysis for 33 individuals, whose
data are summarized in Fig. 7. We considered whether the
Fig. 3 Co-localization of different anti-PTPRG antibodies on the same histo-cytologic structures: murine cerebral cortex (a–d) and vessel sections
(e–h) were analyzed using TPγ B9-2 and chPTPRG antibodies. White arrow, a dendrite staining positive for chPTPRG and negative with TPγ B9-2
(b). A slightly different subcellular distribution is also observed in small vessels as shown by overlapping of both stains (in colocalization and
merge mode, c, d, g, h). In colocalization mode, yellow regions indicate only the overlapping epitopes. Merge mode shows signals from the
individual antibodies highlighting the capability of chPTPRG (in red) to identify dendrites that are not recognized by TPγ B9-2 (in green). Slight
differences in staining are present also in vessel sections. These results confirm the presence of different Ptprg isoforms recognized by the
antibodies and localized in different cellular structures. DAPI (blue) stains nuclei. Scale bars, 30 μm in a–d, 10 μm in e–h
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failure to achieve a major molecular response (MMR) was
associated with decreased/absent recovery of PTPRG. For
patients achieving MMR (p = 0.008) and for those with
intermediate responses (p = 0.0216; no MMR), PTPRG
levels showed a significant increase when baseline was
compared to follow-up after treatment. However, the few
patients who proved to be non-responsive to treatment
(NR) displayed the lowest PTPRG mRNA levels that did
not increase following treatment (Fig. 7). Finally, we ana-
lyzed fresh peripheral blood samples from three patients
at diagnosis and following successful TKI-based therapy.
In these cases, downregulation of PTPRG protein expres-
sion was confirmed at diagnosis, while its expression
recovered in tandem with the return of Philadelphia-
negative hematopoiesis and achievement of MMR in
response to effective TKI treatment (Fig. 8a–c).
Discussion
PTPRG is emerging as a key tumor suppressor gene in
many types of neoplasia [5, 7, 23–25]. More recently, an
oncosuppressive role has been described in selected
hematologic malignancies [8, 26], suggesting that the
availability of an antibody suitable for flow cytometric
applications would represent a valuable tool with poten-
tial clinical applications. In this study, we present the
characterization of the first monoclonal antibody
raised against the ECD of human PTPRG, expressed
and purified from the HEK293F human cell line,
which was found suitable for different immunoassay
applications, including flow cytometry. This monoclo-
nal antibody (named TPγ B9-2) appears capable of
recognizing murine and human PTPRG by immuno-
fluorescence, immunohistochemistry, and flow cytom-
etry and its reactivity overlaps almost entirely with
the tissue structures recognized by another validated
polyclonal antibody, chPTPRG, raised against a pep-
tide present in the ECD of PTPRG [10].
Of interest is the observation that TPγ B9-2 displays
a slightly different subcellular reactivity, although rec-
ognizing overlapping structures in human and murine
tissues, suggesting its capability to recognize a distinct
epitope associated with a specific isoform. The presence
of PTPRG isoforms was described in previous work
carried out in rats [22], humans, and mice [19, 21]. This
observation might also help to explain slight differences
in reactivity found in normal and neoplastic samples (in
both hematological and solid tissue samples) that will
need to be further evaluated in future studies. Import-
antly, both antibodies confirmed that PTPRG is down-
regulated in the leukocytes of patients affected by
Fig. 4 Flow cytometric analysis of healthy human donor peripheral blood samples using two anti-PTPRG antibodies. Dot plots show gating strategy for
each cell subset analyzed in histograms. N = 34 monocytes, N = 20 T cells, N= 26 B cells, N = 16 neutrophils, N= 10 eosinophils, and N = 18 CD34+ cells.
PTPRG expression in peripheral blood circulating monocytes (CD45+; CD14+), T cells (CD45+; CD3+), B cells (CD45+; CD19+), PMN neutrophils (CD45+;
CD16+), PMN eosinophils (CD45+; CD16−), CD34+ progenitor cells (CD45low; CD34+), using the reference antibody chPTPRG and TPγ B9-2. Data are
expressed as mean fluorescence intensity (MFI) with appropriate isotype controls (preimmune chicken IgY and irrelevant murine IgG1) as references
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CML, including CD34+CD38bright and CD34+CD38dim
hematopoietic precursors. This observation implies that
its loss occurs at the stage of early hematopoietic pre-
cursors. PTPRG is a tumor suppressor gene capable of
interfering with BCR-ABL1 signaling by decreasing
BCR-ABL1-dependent tyrosine phosphorylation in
CML cells [8]. Its downregulation in all CD34+ frac-
tions of CML patients along with the demonstration that
its forced up- and downregulation in CML cells reduces
and increases, respectively, clonogenic capacity [8], suggest-
ing a key role in the maintenance of the disease. The role of
PTPRG in controlling hematopoietic cell survival/differenti-
ation is further supported by an early study [3], while the
most recent evidence linking PTPRG to the pathogenesis of
leukemia would be in keeping with inhibition of PTPRG
expression by epigenetic regulation consisting in methyla-
tion of selected promoter regions and the fact that its
downregulation cooperates with RAS gene activation in
childhood acute lymphoblastic leukemia (ALL) [26]. This
last study adds another hematological malignancy to
the number of diseases where deregulated PTPRG is
disease associated. Of additional interest is the new
observation that TPγ B9-2 antibody is capable of de-
tecting PTPRG expression in non-CML hematopoietic
cells re-emerging in the same patient after effective
therapy, thus confirming that normal hematopoiesis
does require an appropriate level of PTPRG expres-
sion, and the latter is specifically downregulated in
the diseased cells. Under these carefully controlled
conditions (same individuals-same antigen) an anti-
body found specific for PTPRG binds to the cell sur-
face after TKI therapy. This suggests that the antigen
is now expressed as happens for normal individuals.
Very few examples of cell surface biomarkers specific-
ally expressed in CML are available in the literature;
however, the ones described are expressed on the cell
surface and not downregulated or lost, like PTPRG,
in CML cells. Among these, RNA expression analysis
Fig. 5 Flow cytometric analysis using TPγ B9-2 antibody of normal individuals and CML patients. Representative flow cytometric analysis of a normal
individual (a) and a CML patient (b) performed with both chicken and Mab for comparison. c Comparison made using mean fluorescence intensities
(MFI) values obtained with TPγ B9-2. d PTPRG expression in CD34+, CD34+CD38bright, CD34+CD38dim subpopulations from 13 G-CSF mobilized normal
individuals and 24 CML patients. MFI values obtained calculating the ratio between the signal derived from TPγ B9-2 and irrelevant murine IgG1,
respectively (p values for statistic derive from Mann-Whitney test)
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identified an association between low CD7 expression
along with high expression of proteinase 3 or elastase
with longer survival in CML [27]. An association was
described between hypomethylation of CD7 promoter
region and its increased expression [11] The orphan
receptor tyrosine kinase ROR1 was shown to be expressed
in follicular lymphoma. Also, chronic lymphocytic
leukemia, hairy cell leukemia, and CML had significantly
higher numbers of ROR1+ cells [13]. Sperm-associated
antigen 9 (SPAG9) mRNA and protein were found to be
expressed in CML patients (88%) and have been associ-
ated with humoral response against this antigen in 90% of
the cases, suggesting it as a potential biomarker and/or
immunotherapeutic target [12]. No specific functional
roles in CML have been associated with this gene product.
A proteomic survey of cell surface proteins in leukemia
cell lines identified 25 proteins, including CD43 and
CD98, which appeared to be differentially expressed in
CML cell lines, with CD43 expressed uniquely in K562
cells [28]. More recently, a series of genes were identified
by transcriptome analysis [14]. Both IL1RAP and
CD26 can be regarded as promising candidates as
CML-specific antigens in the CD34+CD38− CML LSC
population [15–17]. Within this context, PTPRG has
unique features as it is specifically downregulated in
CML and has been demonstrated to have a functional
role being capable of binding and dephosphorylating
the driving oncoprotein BCR-ABL1 and consequently
reducing total and specific phosphotyrosine levels as
well as clonogenic capacity in various CML cells [8].
Of interest is the recent observation that JAK2 kinase,
a key signaling molecule involved in BCR-ABL1-
driven pathways [29], represents a bona fide PTPRG
substrate [30].
Fig. 7 PTPRG mRNA expression in paired samples of patients treated
with TKI. RQ-PCR analysis of PTPRG expression in peripheral blood
(gray symbols) and bone marrow (black symbols) calculated as % vs
ABL1 mRNA. Major molecular response (MMR) is associated with
recovery of PTPRG expression. Only the few non-responder patients
failed to recover PTPRG expression
Fig. 6 Evaluation of sensitivity and specificity of the test. A receiver operating characteristic curve (ROC curve) was built for normal individuals vs
CML patients. Data obtained with TPγ B9-2 derived from patients shown in Fig. 5. A statistically significant capability to discriminate between CML
and healthy subject is achieved when monocytes and PMN are evaluated. No/negligible expression of PTPRG in lymphocytes renders these cells
unsuitable for the purpose
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Conclusions
PTPRG represents a remarkable example of a surface pro-
tein biomarker with a specific oncosuppressive mechan-
ism intersecting with BCR-ABL1 and key elements in its
signaling pathway, making it an attractive target for the
development of dedicated reagents, such as specific ago-
nists [30]. Indeed, the development of a specific monoclo-
nal antibody is expected to help unravel the complex
biological role of this phosphatase. The evaluation of
larger series of leukemia samples (myeloproliferative
diseases, CML, and ALL) for PTPRG expression by flow
cytometry, in addition to in situ techniques, as well as the
detailed definition of its signaling pathway, may reveal
additional details regarding CML biology. This in turn
might pave the way for the evaluation of its suitability for
clinical application by supporting diagnosis and follow-up
of these disorders and as a potential therapeutic target.
Additional file
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